NUWE
Nuwellis, Inc.
There isn't enough reported data to score NUWE yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
NUWE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
NUWE's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NUWE PE Valuation
NUWE has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
NUWE Forward outlook
There aren't enough analyst estimates for NUWE to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
NUWE Earnings Per Share
NUWE and NVO do not have enough comparable growth data to identify a winner.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
NUWE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.2M | -0.2% |
| Q2 2026 | $2M | +14% |
| Q1 2026 | $2.4M | +26% |
| Q4 2025 | $2.4M | +4.4% |
| Q3 2025 | $2.2M | -6.3% |
| Q2 2025 | $1.7M | -21% |
| Q1 2025 | $1.9M | +2.5% |
| Q4 2024 | $2.3M | -9% |
NUWE's revenue is growing: $2M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -93% | +29 points |
| Q2 2026 | -161% | +7.5 points |
| Q1 2026 | -190% | -29 points |
| Q4 2025 | -101% | +2 points |
| Q3 2025 | -122% | -57 points |
| Q2 2025 | -168% | -63 points |
| Q1 2025 | -161% | +95 points |
| Q4 2024 | -103% | +38 points |
NUWE's operating margin was −93% last quarter, up 29 points from the same quarter a year ago, near the top of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over NUWE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over NUWE on profitability, with a higher operating margin.
NUWE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3M | +$282K |
| Q2 2026 | -$3.2M | -$1.1M |
| Q1 2026 | -$3.1M | -$606K |
| Q4 2025 | -$3M | -$1.5M |
| Q3 2025 | -$3.2M | -$790K |
| Q2 2025 | -$2.1M | +$677K |
| Q1 2025 | -$2.5M | +$355K |
| Q4 2024 | -$1.5M | +$1.2M |
NUWE has burned cash in almost every quarter: −$12M over the past year, against −$9M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over NUWE on cash generation, producing positive trailing cash flow while its opponent burns cash.
NUWE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +206% | +13.6K shares |
| 1 year | +2984% | +19.5K shares |
| 3 years | +671167% | +20.1K shares |
NUWE has 20,138 diluted shares, up 2984% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over NUWE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
NUWE Net Leverage
NUWE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
NUWE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.7 | Oversold |
| Stochastic | 12.8 | Oversold |
NUWE's weekly RSI is 26 (oversold) and its Stochastic is 13 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
NUWE PE vs Healthcare Sector
NUWE has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NUWE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.32 | 5.5% below |
| 20 week MA | $11.2 | 55% below |
| 50 week MA | $277.8 | 98% below |
| 100 week MA | $4,134.8 | 100% below |
| 200 week MA | $387,796.3 | 100% below |
NUWE is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over NUWE on trend strength, trading above more of its moving averages.
NUWE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,168,052,886.0 | $339,415,650.0 | -71% |
| 2021 | $339,415,650.0 | $56,955,150.0 | -83% |
| 2022 | $56,955,150.0 | $3,519,180.0 | -94% |
| 2023 | $3,519,180.0 | $268,985.8 | -92% |
| 2024 | $268,985.8 | $15,479.1 | -94% |
| 2025 | $15,479.1 | $642.6 | -96% |
| 2026 YTD | $642.6 | $5.03 | -99% |
NUWE has finished every year since 2020 lower, and it's down 99% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over NUWE on returns for 2026, with the stronger performance.